Supercharging Immunotherapy

fancy black and blue t-cell 3d scientific images immune system

To reprogram the immune system to help overcome cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

15 Feb 2019

Michael A. Kelly is a former senior executive of Amgen, Inc. currently acting...

2 Jan 2019

The agreement grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave®...

17 Dec 2018

The Phase 2 clinical trial evaluates the safety and efficacy of HB-101

6 Dec 2018

Valneva is a biotech company developing and commercializing vaccines for...

28 Nov 2018

DarwinHealth is a precision-focused cancer medicine company, utilizing...

14 Nov 2018

A business professional with more than two decades of executive experience in...

all news

The source of Hookipa’s strength lies in our people. We value individuals and human rights. We value teamwork. We value diversity - gender, race, nationality, character. We value respect. We want to continue to grow fast as a company and develop as individuals. Get in touch to know more about our career opportunities!

Supercharging Immunotherapy

Our Mission

News

HOOKIPA Appoints Michael A. Kelly as Independent Director

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License...

HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic...

Valneva and HOOKIPA Sign a Collaboration and Manufacturing Agreement

HOOKIPA and DarwinHealth Enter into a Research Collaboration and License...

HOOKIPA Appoints Julie O’Neill as a Non-Executive Director

Our Pipeline

Careers